美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

新桥生物

4.18

+0.19004.76%

盘后：4.230.0453+1.08%19:59 EST

成交量：45.04万

成交额：184.20万

市值：4.82亿

市盈率：-8.53

高：4.18

开：4.03

低：3.90

收：3.99

52周最高：6.79

52周最低：0.5950

股本：1.15亿

流通股本：4,823.40万

量比：0.97

换手率：0.93%

股息：- -

股息率：- -

每股收益(TTM):-0.4902

每股收益(LYR):-0.2738

净资产收益率：-18.46%

总资产收益率：-10.36%

市净率：2.45

市盈率(LYR):-15.27

数据加载中...

总览公司新闻资讯公告

新桥生物宣布将在ESMO-IO大会上公布Ragistomig扩展性1期临床数据

新桥生物子公司Visara任命两位眼科领域杰出领袖为首席医学官和科学顾问委员会主席，加速推进 VIS-101 的全球开发进程

新桥生物盘中异动下午盘急速跳水5.08%

新桥生物盘中异动快速上涨5.75%

医药界“泡泡玛特”：递表港交所

新桥生物递表港交所，主要专注于开发自主研发的创新型精准免疫肿瘤药物

I-MAB（Nasdaq: IMAB）正式更名为新桥生物（NovaBridge Biosciences；Nasdaq: NBP），股票交易将于2025年10月30日正式生效，新品牌标志着其向全球生物科技平台型公司的战略转型

I-Mab （纳斯达克：IMAB）将于2025年10月30日转型为Novabridge Biosciences （纳斯达克：NBP），全新品牌和标志将体现向全球生物科技平台的战略转型

Biotech资产出海迎多重“大考”：交易条款里的长期挑战

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NBP/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新桥生物","latestPrice":4.18,"timestamp":1764968400000,"preClose":3.99,"halted":0,"volume":450445,"hourTrading":{"tag":"盘后","latestPrice":4.2253,"preClose":4.18,"latestTime":"19:59 EST","volume":13488,"amount":56433.267,"timestamp":1764982793530},"delay":0,"floatShares":48234000,"shares":115266053,"eps":-0.490217,"marketStatus":"休市中","change":0.19,"latestTime":"12-05 16:00:00 EST","open":4.03,"high":4.18,"low":3.9,"amount":1841983.3423624998,"amplitude":0.070175,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.490217,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":3.99,"preHourTrading":{"tag":"盘前","latestPrice":4.09,"preClose":3.99,"latestTime":"09:27 EST","volume":2489,"amount":9996.983874000001,"timestamp":1764944840444},"postHourTrading":{"tag":"盘后","latestPrice":4.2253,"preClose":4.18,"latestTime":"19:59 EST","volume":13488,"amount":56433.267,"timestamp":1764982793530},"volumeRatio":0.9748541329085144,"impliedVol":1.7461,"impliedVolPercentile":0.3846},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":48234000,"roa":"-10.36%","roe":"-18.46%","lyrEps":-0.273814,"volumeRatio":0.9748541329085144,"shares":115266053,"dividePrice":0,"high":4.18,"amplitude":0.070175,"preClose":3.99,"low":3.9,"week52Low":0.595,"pbRate":"2.45","week52High":6.79,"institutionHeld":0,"latestPrice":4.18,"eps":-0.490217,"divideRate":0,"volume":450445,"delay":0,"ttmEps":-0.490217,"open":4.03,"prevYearClose":0.85,"prevWeekClose":3.84,"prevMonthClose":3.84,"prevQuarterClose":3.78,"fiveDayClose":3.84,"twentyDayClose":4.19,"sixtyDayClose":3.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"盘前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"NBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2024-08-28","symbol":"NBP","fiscalQuarterEnding":"2024/06","expectedEps":-0.51,"name":null,"time":"盘前","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"pre","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1759467600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2025-12-05","current":-8.526836,"percent":0.75,"low":-14.267741,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"high":-10.607129,"avg":-12.08175,"sd":0.855232,"marketCap":459911551},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551}],"updateTime":1765095941078},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589836892","title":"新桥生物宣布将在ESMO-IO大会上公布Ragistomig扩展性1期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589836892","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589836892?lang=zh_cn&edition=fundamental","pubTime":"2025-12-04 20:58","pubTimestamp":1764853080,"startTime":"0","endTime":"0","summary":"Ragistomig是一款4-1BB × PD-L1双特异性抗体，旨在治疗使用检查点抑制剂后病情复发或效果欠佳的患者。该研究的主要终点是确定ragistomig的剂量限制性毒性和不良事件特征，并观察客观缓解率、药物代谢动力学和免疫原性特征以及其他次要终点。公司的差异化管线主要由givastomig和VIS-101领衔。givastomig正开发用于治疗Claudin 18.2阳性的胃癌及其他胃肠道恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4839442_ZH39442_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2585171117","title":"新桥生物子公司Visara任命两位眼科领域杰出领袖为首席医学官和科学顾问委员会主席，加速推进 VIS-101 的全球开发进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2585171117","media":"美通社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585171117?lang=zh_cn&edition=fundamental","pubTime":"2025-11-21 14:02","pubTimestamp":1763704920,"startTime":"0","endTime":"0","summary":"两位专家将为VIS-101项目带来宝贵的临床开发专业知识。作为 首席医学官，Rich 博士将全面负责 Visara 的临床职能与研发项目；Quezada-Ruiz 博士则将领导新成立的科学顾问委员会。他们的加入进一步印证了 VIS-101 的巨大潜力，也展现了 Visara 打造世界级组织的决心。\" Visara首席医学官Rich博士表示：\"我致力于通过制定高效的临床及监管策略，加速创新眼科疗法的研发进程，使其尽快惠及患者。我期待与Visara 团队合作，完成II 期研究并推动VIS-101 进入注册开发阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4830740_ZH30740_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["VIS","BK4585","BK4139","NBP","BK4588"],"gpt_icon":0},{"id":"2585549791","title":"新桥生物盘中异动 下午盘急速跳水5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585549791","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585549791?lang=zh_cn&edition=fundamental","pubTime":"2025-11-21 02:37","pubTimestamp":1763663868,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日02时37分，新桥生物股票出现波动，股价急速下挫5.08%。截至发稿，该股报4.30美元/股，成交量27.6417万股，换手率0.24%，振幅8.83%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。新桥生物股票所在的生物技术行业中，整体涨幅为0.51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112102374895111263&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112102374895111263&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2582368829","title":"新桥生物盘中异动 快速上涨5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582368829?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 22:38","pubTimestamp":1762785528,"startTime":"0","endTime":"0","summary":"北京时间2025年11月10日22时38分，新桥生物股票出现异动，股价快速拉升5.75%。截至发稿，该股报4.23美元/股，成交量1.2826万股，换手率0.01%，振幅0.71%。新桥生物股票所在的生物技术行业中，整体涨幅为0.62%。其相关个股中，Cogent Biosciences, Inc.、Inflarx N.V.、Pluri Inc.涨幅较大，Inflarx N.V.、Propanc Biopharma, Inc.、Innate Pharma较为活跃，换手率分别为78.22%、15.29%、8.71%，振幅较大的相关个股有Cogent Biosciences, Inc.、Pluri Inc.、Inflarx N.V.，振幅分别为20.18%、20.06%、17.89%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110223848a49788fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110223848a49788fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2580280025","title":"医药界“泡泡玛特”：递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2580280025","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580280025?lang=zh_cn&edition=fundamental","pubTime":"2025-11-02 08:02","pubTimestamp":1762041764,"startTime":"0","endTime":"0","summary":"VIS-101已在美国和中国完成了初步的安全性和剂量递增研究，目前正在中国完成一项随机剂量范围的II期研究。VIS-101预计将于2026年具备开展III期试验的条件。此次收购已通过新成立的子公司Visara完成的。“我们要做医药行业的‘泡泡玛特’。”傅唯用一个生动的比喻解释，泡泡玛特的核心是“连接设计师与全球渠道”，新桥要做的是“连接中国创新药研发者与全球市场”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102080748a481f874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102080748a481f874&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4211","NBP","BK4139","BK4195","PFS"],"gpt_icon":0},{"id":"2579102884","title":"新桥生物递表港交所，主要专注于开发自主研发的创新型精准免疫肿瘤药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2579102884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579102884?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 07:14","pubTimestamp":1761866058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所10月31日披露，新桥生物向港交所主板提交上市申请书，高盛和中信证券为联席保荐人。招股书显示，新桥生物成立于2016年，是一家采用不限治疗领域发展策略的全球性生物技术平台公司。自成立以来，公司主要专注于开发自主研发的创新型精准免疫肿瘤药物，用于癌症治疗。除givastomig外，截至最后实际可行日期， 新桥生物已建立包含三个临床阶段项目的管线，包括两个肿瘤项目uliledlimab及ragistomig，以及眼科项目VIS-101。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NBP","91167"],"gpt_icon":0},{"id":"2579907397","title":"I-MAB（Nasdaq: IMAB）正式更名为新桥生物（NovaBridge Biosciences；Nasdaq: NBP），股票交易将于2025年10月30日正式生效，新品牌标志着其向全球生物科技平台型公司的战略转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2579907397","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579907397?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 21:56","pubTimestamp":1761746160,"startTime":"0","endTime":"0","summary":"此项更名决议已获得公司于2025年10月24日召开的特别股东大会高票通过，并获董事会批准。在部分第三方网站或应用程序上，若搜索\"NovaBridge Biosciences\"或\"NBP\"时，可能暂时无法查询到公司美国存托股份在2025年10月30日之前的历史交易数据。我们正积极推进givastomig全球随机对照 II 期研究，预计于2026年第一季度完成首例患者入组。VIS-101预计将于2026年具备开展III期试验的条件。此次收购已通过新成立的子公司Visara完成。新桥生物成为Visara的控股股东，并拥有VIS-101的全球权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4810152_ZH10152_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["MAB","TQQQ","PSQ","QLD",".IXIC","TSYW.SI","BK4139","USJW.SI","BK4505","QID","NQmain","MNQmain","USAW.SI","BK4526","NVIW.SI","IMAB","SQQQ","NBP","BK4535"],"gpt_icon":1},{"id":"1176185820","title":"I-Mab （纳斯达克：IMAB）将于2025年10月30日转型为Novabridge Biosciences （纳斯达克：NBP），全新品牌和标志将体现向全球生物科技平台的战略转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1176185820","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176185820?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 21:03","pubTimestamp":1761742984,"startTime":"0","endTime":"0","summary":"I-Mab（纳斯达克：IMAB）将于2025年10月30日转型为Novabridge Biosciences（纳斯达克：NBP），全新品牌和标志将体现向全球生物科技平台的战略转型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4526","BK4139","NBP","IMAB","BK4535"],"gpt_icon":0},{"id":"2579390406","title":"Biotech资产出海迎多重“大考”：交易条款里的长期挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2579390406","media":"研发客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579390406?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 05:00","pubTimestamp":1761685247,"startTime":"0","endTime":"0","summary":"中国Biotech企业应充分认识到NewCo交易的“两步走”本质。《美国优先投资政策》对中国创新药行业的实际影响，最终仍取决于落地的具体细则，中国Biotech行业应当密切关注动向。许可交易频传利好，但签约只是起点据研发客统计，2022年以来中国创新药资产许可交易已达522起。其中不乏百利天恒与BMS的潜在交易总额达84亿美元的合作，成为近年来中国Biotech资产出海的标杆案例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029050226a47a598b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029050226a47a598b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBP","BK4215","BK4139","BK4535","BK4505","CSR","IMAB","NDAA","BK4526"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}